#USA #Medical Devices #Idaho Falls #Radnostix #Calibration Products

Radnostix, Inc. Reports Impressive FY2025 Results

On April 1, 2026, Radnostix, Inc., previously known as International Isotopes Inc., announced its financial outcomes for the fiscal year 2025. With headquarters in Idaho Falls, Idaho, Radnostix stands as a leader in radioisotope technologies, catering to medical, industrial, and research sectors. The company reported total revenues of $13.07 million, marking it as the second-highest annual revenue in its history despite facing targeted supply chain challenges.

Financial Highlights

The company made significant strides in its Calibration & Reference Products segment, reporting an impressive 21% growth, which translated to $4.25 million in sales. This growth was primarily fueled by the launch of new PET-focused products, an increase in international sales, and recovery from last year's Co-57 isotope shortages.

Moreover, the Theranostics Products segment managed to secure $6.84 million in revenue, the second-highest ever for this category, despite various isotope shortages throughout the year. Notably, its generic Sodium Iodide I-131 continues to lead the market as the only U.S.-manufactured version of its kind. Meanwhile, the Cobalt Products segment brought in $1.75 million, bolstered by the completion of a major refurbishment of processing hot cells, which is anticipated to extend asset life significantly and reduce annual waste costs.

Positive Cash Flow and Strategic Improvements

Radnostix generated a positive operating cash flow of $620,000, reflecting effective cost management in light of ongoing raw material challenges. The company also completed the construction of a dedicated manufacturing facility for Calibration & Reference Products and received its initial NRC license amendment. This positions Radnostix for great potential in capacity expansion and portfolio growth going into 2026.

Future Outlook and Growth Initiatives

Describing the previous year as a period of refinement, CEO Shahe Bagerdjian pointed out that 2025 was integral in establishing groundwork for future success. There was substantial investment in facility upgrades and advancements in their Medical Devices pipeline, enhancing their stature as a reliable domestic supplier of high-value radioisotope products. Among the highlights are the anticipated 2026 launches of the EasyFill Automated Capsule System and RadVent products, which are set for commercial release by Q3 2026.

Additionally, Radnostix has decided to re-evaluate its strategy towards its previously earmarked assets, regaining control of the DUF6 asset amidst a booming nuclear energy landscape. This newfound focus might pave the way for further developments in uranium-related activities, responding to the global surge in interest surrounding nuclear fuel cycle services.

Summary of Radnostix's Key Financial Metrics for FY2025

• - Total Revenue: $13,070,336
• - Gross Profit: $7,702,656
• - Operating Expense: $8,658,843
• - Net Loss: $(908,002)

The company has experienced fluctuations in its income metrics yet seeks to leverage its robust foundation and the anticipated market growth to navigate challenges ahead. In summary, Radnostix's performance in FY2025 showcases its resilience through strategic growth in key product segments, strong operational efficiency, and an optimistic outlook as it positions itself for the future amid an evolving market landscape.

For further information about Radnostix and its offerings, visit www.radnostix.com.